On Wednesday, Boston Scientific experienced a loss of nearly one-fifth of its market capitalization in a single trading ...

Boston Scientific grew sales and adjusted earnings per share by 16% and 14% in the fourth quarter. However, the company's guidance underwhelmed the market. Ultimately, Boston Scientific's earnings ...

Feb 4 (Reuters) - Boston Scientific (BSX.N), opens new tab on Wednesday reported lower-than-expected quarterly sales in its key electrophysiology division, dragging the medical device maker's shares ...

The Boston Scientific Analyst: Analyst Mike Matson maintained a Buy rating, but slashed the price target from $121 to $97. The Boston Scientific Thesis: The company reported revenue of $5.286 billion ...

In October, Boston Scientific announced plans to dive into the peripheral nerve stimulation space through the acquisition of medtech company Nalu Medical. Boston Scientific has been a Nalu investor ...

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income ...

Few analysts foresaw the disappointing results and profit forecast that sent Boston Scientific Corp.’s shares plummeting nearly 20% this week. Even fewer have given up on their bullish calls since. It ...

Boston Scientific expects first quarter 2026 reported revenue growth to be in a range of 10.5% to 12% versus first quarter 2025. Excluding foreign exchange, operational and organic revenue growth for ...

Discover the incredible journey of Boston Dynamics as we explore their rise from MIT research labs to becoming leaders in advanced robotics. This video covers pivotal moments in the company’s history, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Last week, Waymo announced it ...